Let's talk medical research

Keith Lovell joined Antidote as CFO in September 2015, bringing more than 25 years of financial and commercial experience at companies ranging from major blue chip organizations to startups. Prior to Antidote, he was employee number 30 at Shazam, and helped build it up to a billion dollar valuation.

The Scrip Awards are where the industry’s best and brightest are recognized for excellence across the drug development spectrum. That’s why we’re absolutely honored to announce that Antidote has been named a Scrip Awards finalist in the category of “Best Technological Development in Clinical Trials.” We’ve been a finalist in this category before, and are thrilled that the evolution of our ...

A few years ago, we wrote a blog series for ACRP in which we focused on patient centricity in clinical trial design, recruitment, and execution. Over the next few months, we’ll be taking a second look at those blog posts, sharing updated versions on our own blog. Here’s an update to the second in that series.

Clinical research organizations sometimes create surveys and share general statistics about clinical trial participation. But every patient is different, and overarching stats don't tell the full story.

Today, nearly 60 million patients are needed for currently recruiting clinical trials. And in fact, 80% of trials will be delayed or closed due to difficulty finding patients to take part.

As medications become more targeted and sophisticated, the growing complexity of clinical trial protocols is making it more difficult than ever to find the perfect patients for your trials. That’s why a thoughtful and strategic patient recruitment strategy is key.

While approximately 15 to 20 percent of people 65+ have Mild Cognitive Impairment (MCI), it can be difficult to identify, and difficult to determine if it is related to Alzheimer’s disease. MCI does not always lead to dementia, but people with MCI are four times more likely to develop Alzheimer’s disease and other forms of dementia than those without it — so it’s important to treat this condition ...

Today, 70% of the 18 million adults in the U.S. experience moderate-to-severe symptoms. Nearly half of people with eczema report that they "often" or "always" feel frustrated by their disease. One-third report that they spend up to three hours per day treating their disease.

A few years ago, we wrote a blog series for ACRP in which we focused on patient centricity in clinical trial design, recruitment, and execution. Over the next few months, we’ll be taking a second look at those blog posts, sharing updated versions on our own blog. Here’s an update to the first in that series.

An estimated 5.8 million people in the United States have been diagnosed with Alzheimer's disease. As the millions of patients and caregivers around the country know too well, there is not a treatment option that slows or stops disease progression.